What is Indaptus Therapeutics Price-to-Tangible-Book?
As of today (2024-04-25), Indaptus Therapeutics's share price is $2.35. Indaptus Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $1.44. Hence, Indaptus Therapeutics's Price to Tangible Book Ratio of today is 1.64.
The historical rank and industry rank for Indaptus Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
INDP'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.49 Med: 1.22 Max: 1.74
Current: 1.63
During the past 4 years, Indaptus Therapeutics's highest Price to Tangible Book Ratio was 1.74. The lowest was 0.49. And the median was 1.22.
INDP's Price-to-Tangible-Book is ranked better than 69.43% of 1220
companies
in the Biotechnology industry
Industry Median: 2.67
vs INDP: 1.63
A closely related ratio is called PB Ratio. As of today, Indaptus Therapeutics's share price is $2.35. Indaptus Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $1.44. Hence, Indaptus Therapeutics's P/B Ratio of today is 1.64.
Indaptus Therapeutics Price-to-Tangible-Book Historical Data
The historical data trend for Indaptus Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Indaptus Therapeutics's Price-to-Tangible-Book
For the Biotechnology subindustry, Indaptus Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indaptus Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Indaptus Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Indaptus Therapeutics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Indaptus Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Indaptus Therapeutics (Indaptus Therapeutics) Business Description
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INDP has been successfully added to your 